Clinical Trials Directory

Trials / Unknown

UnknownNCT01111981

Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia

Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in the Treatment of Central Centrifugal Cicatricial Alopecia

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Callender Center for Clinical Research · Academic / Other
Sex
Female
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to ascertain the safety and efficacy of Clobetasol Propionate 0.05% E Foam in the treatment of Central Centrifugal Cicatricial Alopecia.

Detailed description

Central Centrifugal Cicatricial Alopecia (CCCA) is an inflammation-induced hair loss starting in the central scalp and progressing centrifugally. The cause of CCCA is unknown. Early diagnosis and treatment is essential to stop or slow the progression of scarring and permanent hair loss. Once scarring occurs, the hair follicles are obliterated and the hair cannot regrow. Thus, anti-inflammatory medications are used to decrease inflammation. Current treatment includes topical and intralesional corticosteroids, oral antibiotics, and hair transplantation, all which may take months to years to show improvement. There is no evidence-based medicine on how to treat primary cicatricial alopecias. Clobestasol Propionate 0.05% Emollient Foam is an FDA-approved and marketed topical corticosteroid for the treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid- responsive dermatoses of the scalp. Many studies found the foam to be less irritating than the original formulation.

Conditions

Interventions

TypeNameDescription
DRUGClobetasol Propionate 0.05% Emollient FoamClobetasol Propionate 0.05% E Foam to be applied to affected area once a day for 16 weeks

Timeline

Start date
2009-10-01
Primary completion
2010-02-01
Completion
2010-10-01
First posted
2010-04-28
Last updated
2010-04-28

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01111981. Inclusion in this directory is not an endorsement.

Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia (NCT01111981) · Clinical Trials Directory